Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 5 | 2022 | 57 | 1.720 |
Why?
|
| Opioid-Related Disorders | 5 | 2022 | 256 | 1.460 |
Why?
|
| Retinopathy of Prematurity | 4 | 2023 | 81 | 0.920 |
Why?
|
| Laser Coagulation | 3 | 2019 | 56 | 0.810 |
Why?
|
| Bevacizumab | 3 | 2019 | 255 | 0.770 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 280 | 0.720 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 94 | 0.690 |
Why?
|
| Narcotic Antagonists | 3 | 2022 | 181 | 0.690 |
Why?
|
| Virtual Reality | 1 | 2021 | 40 | 0.670 |
Why?
|
| Analgesics, Opioid | 5 | 2022 | 540 | 0.630 |
Why?
|
| Naloxone | 2 | 2022 | 80 | 0.620 |
Why?
|
| Fluorescein Angiography | 2 | 2019 | 81 | 0.570 |
Why?
|
| Drug Overdose | 1 | 2019 | 103 | 0.530 |
Why?
|
| Medicare | 1 | 2018 | 467 | 0.440 |
Why?
|
| Cataract | 6 | 2007 | 87 | 0.390 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 55 | 0.350 |
Why?
|
| Lens Implantation, Intraocular | 3 | 2002 | 23 | 0.340 |
Why?
|
| Cataract Extraction | 4 | 2007 | 31 | 0.310 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 54 | 0.310 |
Why?
|
| Aphakia, Postcataract | 2 | 1999 | 4 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3272 | 0.270 |
Why?
|
| Visual Acuity | 7 | 2008 | 191 | 0.240 |
Why?
|
| Infant | 13 | 2019 | 3328 | 0.220 |
Why?
|
| Fentanyl | 2 | 2022 | 92 | 0.210 |
Why?
|
| Lens Capsule, Crystalline | 2 | 2002 | 11 | 0.200 |
Why?
|
| Humans | 34 | 2023 | 98076 | 0.190 |
Why?
|
| Ketamine | 1 | 2021 | 31 | 0.170 |
Why?
|
| Intravitreal Injections | 2 | 2019 | 69 | 0.170 |
Why?
|
| Methadone | 1 | 2021 | 54 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 4 | 1995 | 44 | 0.160 |
Why?
|
| Female | 21 | 2022 | 51535 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 189 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2019 | 10972 | 0.150 |
Why?
|
| Cranial Nerve Neoplasms | 3 | 1995 | 12 | 0.150 |
Why?
|
| Optic Nerve Diseases | 3 | 1995 | 16 | 0.150 |
Why?
|
| Barotrauma | 1 | 1999 | 3 | 0.150 |
Why?
|
| Child, Preschool | 15 | 2019 | 4001 | 0.150 |
Why?
|
| Play and Playthings | 1 | 1999 | 9 | 0.140 |
Why?
|
| Carboplatin | 2 | 2018 | 331 | 0.140 |
Why?
|
| Eye Injuries | 1 | 1999 | 15 | 0.140 |
Why?
|
| Pain | 1 | 2021 | 416 | 0.140 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1998 | 1 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 244 | 0.130 |
Why?
|
| Retinal Neoplasms | 2 | 2008 | 12 | 0.130 |
Why?
|
| Retinoblastoma | 2 | 2008 | 30 | 0.130 |
Why?
|
| Lens Diseases | 1 | 2017 | 2 | 0.130 |
Why?
|
| SEER Program | 1 | 2018 | 243 | 0.130 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1999 | 119 | 0.130 |
Why?
|
| Eye Infections, Fungal | 1 | 2017 | 12 | 0.130 |
Why?
|
| Candida albicans | 1 | 2017 | 32 | 0.130 |
Why?
|
| Endophthalmitis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 4823 | 0.130 |
Why?
|
| Candidiasis | 1 | 2017 | 40 | 0.130 |
Why?
|
| Abscess | 1 | 2017 | 94 | 0.130 |
Why?
|
| Male | 18 | 2022 | 47075 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2018 | 483 | 0.120 |
Why?
|
| Lens, Crystalline | 1 | 2017 | 67 | 0.120 |
Why?
|
| Asthma | 2 | 2022 | 1078 | 0.120 |
Why?
|
| Incidence | 2 | 2018 | 1779 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 661 | 0.110 |
Why?
|
| Recurrence | 1 | 2018 | 1254 | 0.110 |
Why?
|
| Infant, Newborn | 6 | 2023 | 2529 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 634 | 0.100 |
Why?
|
| Algorithms | 1 | 2022 | 2002 | 0.100 |
Why?
|
| Infant, Premature | 3 | 2023 | 305 | 0.100 |
Why?
|
| Eye | 2 | 1984 | 113 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2658 | 0.100 |
Why?
|
| Eyelids | 1 | 2013 | 20 | 0.100 |
Why?
|
| Facial Muscles | 1 | 2013 | 23 | 0.100 |
Why?
|
| Child | 12 | 2007 | 7681 | 0.100 |
Why?
|
| Oculomotor Muscles | 1 | 2013 | 27 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2018 | 3212 | 0.100 |
Why?
|
| Tendons | 1 | 2013 | 47 | 0.100 |
Why?
|
| Optic Chiasm | 1 | 1992 | 17 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 1992 | 39 | 0.090 |
Why?
|
| Microphthalmos | 1 | 2008 | 7 | 0.070 |
Why?
|
| Skin Abnormalities | 1 | 2008 | 12 | 0.070 |
Why?
|
| Limb Deformities, Congenital | 1 | 2008 | 17 | 0.070 |
Why?
|
| Laser Therapy | 2 | 2008 | 149 | 0.070 |
Why?
|
| United States | 2 | 2019 | 8196 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2008 | 31 | 0.070 |
Why?
|
| Refraction, Ocular | 2 | 2019 | 11 | 0.070 |
Why?
|
| Podophyllotoxin | 1 | 2007 | 9 | 0.070 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2007 | 47 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 100 | 0.060 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 28 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7389 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 77 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 235 | 0.060 |
Why?
|
| Adolescent | 10 | 2008 | 10079 | 0.060 |
Why?
|
| Adult | 7 | 2019 | 29538 | 0.060 |
Why?
|
| Amblyopia | 1 | 2006 | 6 | 0.060 |
Why?
|
| Sensory Deprivation | 1 | 2006 | 32 | 0.060 |
Why?
|
| Eyeglasses | 1 | 2006 | 8 | 0.060 |
Why?
|
| Aged | 4 | 2021 | 21758 | 0.060 |
Why?
|
| Vitrectomy | 3 | 2003 | 48 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 272 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 642 | 0.050 |
Why?
|
| Eye Diseases | 1 | 1984 | 58 | 0.050 |
Why?
|
| Vision Tests | 1 | 1983 | 18 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 1983 | 73 | 0.050 |
Why?
|
| Retinal Detachment | 1 | 2003 | 61 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 169 | 0.050 |
Why?
|
| Administration, Sublingual | 1 | 2022 | 6 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 8 | 0.050 |
Why?
|
| Skin Diseases | 1 | 1984 | 176 | 0.050 |
Why?
|
| Pseudophakia | 2 | 2002 | 3 | 0.050 |
Why?
|
| Gestational Age | 1 | 2023 | 340 | 0.040 |
Why?
|
| Receptors, Opioid, mu | 1 | 2021 | 50 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 74 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 400 | 0.040 |
Why?
|
| Public Health | 1 | 2022 | 161 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 849 | 0.040 |
Why?
|
| Iris Diseases | 1 | 1999 | 5 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 1999 | 27 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 839 | 0.040 |
Why?
|
| Corneal Diseases | 1 | 1999 | 29 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2021 | 108 | 0.040 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Injections | 1 | 2019 | 131 | 0.040 |
Why?
|
| Hearing Loss | 1 | 2019 | 68 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 100 | 0.030 |
Why?
|
| Vision, Binocular | 1 | 1998 | 22 | 0.030 |
Why?
|
| Time Factors | 3 | 2019 | 5567 | 0.030 |
Why?
|
| Risk Factors | 3 | 2023 | 6232 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 4025 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 726 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 245 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1384 | 0.030 |
Why?
|
| Recovery of Function | 1 | 1999 | 370 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 83 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 126 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 916 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 1995 | 8 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 438 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 1995 | 62 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2008 | 9711 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1995 | 85 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 511 | 0.030 |
Why?
|
| Age Factors | 4 | 2006 | 1962 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1950 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3244 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Blepharoptosis | 1 | 2013 | 8 | 0.020 |
Why?
|
| Fasciotomy | 1 | 2013 | 20 | 0.020 |
Why?
|
| Theophylline | 1 | 1993 | 34 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 202 | 0.020 |
Why?
|
| Glioma | 1 | 1994 | 309 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 29427 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1751 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 56 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 764 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Blindness | 1 | 2008 | 39 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 2007 | 23 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2007 | 30 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 205 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 207 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 1984 | 12 | 0.010 |
Why?
|
| Sturge-Weber Syndrome | 1 | 1984 | 9 | 0.010 |
Why?
|
| Pigmentation Disorders | 1 | 1984 | 13 | 0.010 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1984 | 16 | 0.010 |
Why?
|
| Tuberous Sclerosis | 1 | 1984 | 27 | 0.010 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 6 | 0.010 |
Why?
|
| Dapsone | 1 | 1984 | 11 | 0.010 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1984 | 17 | 0.010 |
Why?
|
| Ocular Physiological Phenomena | 1 | 1983 | 10 | 0.010 |
Why?
|
| Strabismus | 1 | 1983 | 8 | 0.010 |
Why?
|
| Prednisone | 1 | 1984 | 251 | 0.010 |
Why?
|
| Cats | 1 | 1983 | 281 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 1983 | 76 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1610 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 1094 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1983 | 524 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1992 | 2666 | 0.010 |
Why?
|
| Child Development | 1 | 1983 | 179 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 138 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1983 | 245 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1535 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3605 | 0.010 |
Why?
|
| Miotics | 1 | 1999 | 2 | 0.010 |
Why?
|
| Pilocarpine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Corneal Edema | 1 | 1999 | 5 | 0.010 |
Why?
|
| Visual Perception | 1 | 1983 | 341 | 0.010 |
Why?
|
| Aging | 1 | 1983 | 770 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1983 | 2572 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 360 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 118 | 0.010 |
Why?
|
| Body Temperature | 1 | 1993 | 127 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 412 | 0.010 |
Why?
|
| Fever | 1 | 1993 | 122 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1993 | 111 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 889 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1994 | 1284 | 0.000 |
Why?
|
| Epiglottis | 1 | 1984 | 6 | 0.000 |
Why?
|
| Complement C3 | 1 | 1984 | 62 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1984 | 82 | 0.000 |
Why?
|
| Basement Membrane | 1 | 1984 | 58 | 0.000 |
Why?
|
| Animals | 1 | 1983 | 28894 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 310 | 0.000 |
Why?
|
| Radiography | 1 | 1984 | 764 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 480 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1984 | 1567 | 0.000 |
Why?
|